Cardiology Perspective

 
 

  • Apr 11 2025 This Week in Cardiology  
  • Beyond BMI: Weight Loss Produces More Health Benefits   Dr Sarah Barenbaum discusses realistic weight-loss goals.
  • ISC 2025 Thrombectomy in Distal Stroke Overreach or Fine Tuning?   The DISTAL and ESCAPE MeVO trials were neutral for thrombectomy in distal vessel occlusions — were the patients who would benefit simply not enrolled and what will the investigators do going forward?
  • ACC 2025 Little Learned From Trials That Are Positive by Design Dapagliflozin after TAVI? Semaglutide for claudication? Two trials designed to be positive should not warrant new indications for these drugs writes John Mandrola, MD.
  • For America First, Invest in Science and the NIH   Panel discussion of a Presidential Advisory from the American Heart Association that outlines the importance of funding for scientific research and the need for a robust National Institutes of Health.
  • Know SSRI Side Effects Dr. Paauw warns about common side effects of selective serotonin reuptake inhibitors that may be seen in primary care.
  • ACC 2025 Fluid Restriction in HF: Let’s Not Torture Patients   Drs Piña and Hsich discuss the FRESH-UP trial that challenged the dogma of fluid restriction in heart failure and provide practical strategies for optimizing medical therapy instead.
  • Can Europe Fill the Gap in Global Research Left by US Cuts? In this interview, Gilles Montalescot, MD, PhD, discusses the significant impact of US funding cuts on global medical research and the potential for Europe to step in.
  • The Management of Hypercalcemia in Primary Care   Primary hyperparathyroidism and malignancy account for around 90% of all cases of hypercalcemia in primary care.
  • Apr 04 2025 This Week in Cardiology   Trials from the 2025 American College of Cardiology scientific sessions, including the WARRIOR, PROTECT TAVI, DAPATAVI, and SOUL are reviewed by John Mandrola, MD
  • ACC 2025 Keep Fighting INOCA After Neutral WARRIOR Trial   Drs O’Donoghue, Handberg, and Bairey-Merz discuss the WARRIOR trial of intensive medical therapy in women with nonobstructive symptomatic CAD, presented at the ACC 2025 Scientific Session.
  • Menopausal Hormone Therapy Isn't as Scary as You Think   Menopausal hormone therapy has been associated with increased risks for breast cancer, heart disease, and stroke — but are the risks worth the benefits? Dr Christopher Labos thinks so.
  • Should Medicine Be Boring? Heroic high-stakes medicine should be left to TV doctors, because the most effective care is performed with a level of precision bordering on the mechanical and the mundane.
  • Gene Therapy: Medical Progress Has a Price, Says Ethicist   Ethicist Art Caplan discusses progress in gene therapy research and the need for medical professionals and regulators to tolerate appropriate risk.
  • No AI System Will Ever Replace Physicians: Jha   New tech may seem threatening, and MDs might feel “under attack.” But Jha says every future innovation only makes the physician’s role more important.
  • Mar 28 2025 This Week in Cardiology   Stopping oral anticoagulation after AF ablation, the core problem with paradoxes like the smoker’s paradox, chronic total occlusion PCI, and an ACC/EHRA preview are discussed by John Mandrola, MD, in this week’s podcast.
  • Medscape Cardiologists and Suicide Report 2025 Cardiologists reveal whether they, or colleagues, have contemplated suicide. They also discuss factors behind the suicide issue and where doctors can turn for help.
  • The Ethical Consequences of the New Administration   Ethicist Art Caplan discusses the ethical consequences of the new administration.
  • Coaching Boosts GLP-1 Effectiveness in Managing Weight Loss Regaining weight after discontinuing GLP-1s is common, but ongoing coaching can help support patients to maintain their weight loss.
  • When Should You Consider Weight-Loss Meds for Obesity?   Dr Sarah Barenbaum discusses when to consider antiobesity medications.